Inovio Pharmaceuticals(INO) - 2021 Q4 - Earnings Call Presentation

Company Focus - INOVIO is dedicated to developing DNA medicines and vaccines for infectious diseases, cancer, and HPV-related conditions [5] - The company's technology combines precisely designed plasmids with proprietary smart devices for delivery [5] - INOVIO's DNA medicines can be designed quickly through optimized SynCon® technology [9] COVID-19 and Infectious Diseases - INOVIO is jointly conducting a global Phase 3 trial for INO-4800 with Advaccine, focusing on countries underserved by vaccines [10] - The WHO selected INO-4800 for its global Phase 3 Solidarity Trial Vaccines, enrolling 40,000 participants [11] - Approximately 1 billion doses of Chinese vaccines have been administered to 110 countries, creating a potential market for heterologous boosters [15] HPV Program - In the US, approximately 80 million Americans are currently infected with HPV, with 14 million new infections annually [17] - VGX-3100 Phase 3 REVEAL1 trial achieved statistical significance for primary objective in all evaluable participants: 23.7% in the treatment group vs 11.3% in the placebo group [21] - INO-3107 has completed enrollment of 32 participants in a Phase 1/2 clinical trial for Recurrent Respiratory Papillomatosis (RRP) [25, 26] Immuno-Oncology - In the GBM study, 84.4% of MGMT Unmethylated (Cohort A) and 85.0% of MGMT Methylated (Cohort B) were alive at 12 months [32]